Molnupiravir(EIDD-2801)

Molnupiravir(EIDD-2801) is an orally bioavailable prodrug of the antiviral nucleoside derivative N4- hydroxycytidine (NHC, EIDD-1931). It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase.Molnupiravir exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broadspectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) and coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2. EIDD-2801 has the potential for COVID-19, seasonal and pandemic influenza treatment.

Product	Molnupiravir(EIDD-2801)
CAS No.	2349386-89-4
Synonyms	MK4482; EIDD-2801; Prodrug-EIDD-1931; Uridine, 4-oxime, 5′-(2-methylpropanoate).
SMILES	O[[email protected]@H]([[email protected]]([[email protected]](N1C(N/C(C=C1)=N/O)=O)O2)O)[[email protected]]2COC(C(C)C)=O
InChI	InChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1
InChI key	HTNPEHXGEKVIHG-QCNRFFRDSA-N
Availability	In Stock
MF.	C13H19N3O7	MW.	329.31
Melting Point	N/A	Boiling Point	N/A
Appearance	White powder	Purity	98%
Application	For research use only	Storage	0°C (short term), -20°C (long term), desiccated
COA & NMR	Download	MSDS	Download

 

Reference

[1] Nguyen KH, Nguyen K, Corlin L, Allen JD, Chung M. Changes in COVID-19 vaccination receipt and intention to vaccinate by socioeconomic characteristics and geographic area, United States, January 6 — March 29, 2021. Ann Med 2021;53:1419-1428.

[2] Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med 2021;385:1941-1950.

[3] Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 2020;12(541):eabb5883-eabb5883.

[4] Urakova N, Kuznetsova V, Crossman DK, et al. β-d-N4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J Virol 2018;92(3):e01965-e17.

[5] Cowman K, Guo Y, Pirofski LA, et al. Post-severe acute respiratory syndrome coronavirus 2 monoclonal antibody treatment hospitalizations as a sentinel for emergence of viral variants in New York City. Open Forum Infect Dis 2021;8(8):ofab313-ofab313.